ABUS vs. ALNY
ABUS (Arbutus Biopharma Corporation) and ALNY (Alnylam Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, ABUS returned 0.97%/yr vs 15.34%/yr for ALNY. At a 0.32 correlation, their price movements are largely independent.
Performance
ABUS vs. ALNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ABUS achieves a -9.56% return, which is significantly higher than ALNY's -26.42% return. Over the past 10 years, ABUS has underperformed ALNY with an annualized return of 0.97%, while ALNY has yielded a comparatively higher 15.34% annualized return.
ABUS
- 1D
- 2.11%
- 1M
- -0.91%
- YTD
- -9.56%
- 6M
- -1.81%
- 1Y
- 26.09%
- 3Y*
- 19.02%
- 5Y*
- 8.15%
- 10Y*
- 0.97%
ALNY
- 1D
- 2.26%
- 1M
- -1.79%
- YTD
- -26.42%
- 6M
- -38.18%
- 1Y
- -3.68%
- 3Y*
- 14.74%
- 5Y*
- 14.98%
- 10Y*
- 15.34%
ABUS vs. ALNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ABUS Arbutus Biopharma Corporation | -9.56% | 47.09% | 30.80% | 7.30% | -40.10% | 9.58% | 27.70% | -27.42% | -24.16% | 106.12% |
ALNY Alnylam Pharmaceuticals, Inc. | -26.42% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
Correlation
The correlation between ABUS and ALNY is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Aug 4, 2015 | 0.32 |
The correlation between ABUS and ALNY shifts across timeframes, from 0.19 (1 year) to 0.32 (all time), reflecting how their relationship changes across market environments.
Fundamentals
ABUS:
$849.18M
ALNY:
$40.44B
ABUS:
$0.83
ALNY:
$4.26
ABUS:
5.22
ALNY:
68.62
ABUS:
4.38
ALNY:
9.24
ABUS:
3.26
ALNY:
37.61
ABUS:
$191.45M
ALNY:
$4.29B
ABUS:
$12.30M
ALNY:
$2.51B
ABUS:
$156.13M
ALNY:
$729.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ABUS vs. ALNY — Risk / Return Rank
ABUS
ALNY
ABUS vs. ALNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ABUS | ALNY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.57 | -0.10 | +0.67 |
Sortino ratioReturn per unit of downside risk | 1.05 | 0.11 | +0.93 |
Omega ratioGain probability vs. loss probability | 1.13 | 1.01 | +0.12 |
Calmar ratioReturn relative to maximum drawdown | 1.01 | -0.09 | +1.10 |
Martin ratioReturn relative to average drawdown | 2.56 | -0.16 | +2.72 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ABUS | ALNY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.57 | -0.10 | +0.67 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.15 | 0.31 | -0.16 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.01 | 0.29 | -0.28 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.09 | 0.32 | -0.42 |
Drawdowns
ABUS vs. ALNY - Drawdown Comparison
The maximum ABUS drawdown since its inception was -92.96%, which is greater than ALNY's maximum drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for ABUS and ALNY.
Loading charts...
Drawdown Indicators
| ABUS | ALNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.96% | -83.58% | -9.38% |
Max Drawdown (1Y)Largest decline over 1 year | -25.86% | -42.01% | +16.15% |
Max Drawdown (3Y)Largest decline over 3 years | -36.84% | -42.01% | +5.17% |
Max Drawdown (5Y)Largest decline over 5 years | -63.42% | -42.46% | -20.96% |
Max Drawdown (10Y)Largest decline over 10 years | -92.96% | -59.95% | -33.01% |
Current DrawdownCurrent decline from peak | -64.78% | -40.44% | -24.34% |
Average DrawdownAverage peak-to-trough decline | -68.77% | -30.59% | -38.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.23% | 22.83% | -12.60% |
Volatility
ABUS vs. ALNY - Volatility Comparison
Arbutus Biopharma Corporation (ABUS) has a higher volatility of 11.07% compared to Alnylam Pharmaceuticals, Inc. (ALNY) at 8.81%. This indicates that ABUS's price experiences larger fluctuations and is considered to be riskier than ALNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ABUS | ALNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.07% | 8.81% | +2.26% |
Volatility (6M)Calculated over the trailing 6-month period | 35.99% | 26.06% | +9.93% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.08% | 36.52% | +9.56% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.93% | 48.85% | +6.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 85.53% | 53.68% | +31.85% |
Dividends
ABUS vs. ALNY - Dividend Comparison
Neither ABUS nor ALNY has paid dividends to shareholders.
Financials
ABUS vs. ALNY - Financials Comparison
This section allows you to compare key financial metrics between Arbutus Biopharma Corporation and Alnylam Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ABUS vs. ALNY - Profitability Comparison
ABUS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Arbutus Biopharma Corporation reported a gross profit of 0.00 and revenue of 179.13M. Therefore, the gross margin over that period was 0.0%.
ALNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 1.17B. Therefore, the gross margin over that period was 0.0%.
ABUS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Arbutus Biopharma Corporation reported an operating income of 168.91M and revenue of 179.13M, resulting in an operating margin of 94.3%.
ALNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 268.64M and revenue of 1.17B, resulting in an operating margin of 23.0%.
ABUS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Arbutus Biopharma Corporation reported a net income of 169.70M and revenue of 179.13M, resulting in a net margin of 94.7%.
ALNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 205.99M and revenue of 1.17B, resulting in a net margin of 17.7%.
Frequently Asked Questions
ABUS and ALNY have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ABUS has higher volatility (11.07%) compared to ALNY (8.81%). In terms of maximum drawdown, ABUS dropped -92.96% vs ALNY's -83.58%.
ABUS currently has the higher Sharpe Ratio (0.57 vs -0.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ABUS and ALNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer